Could a safer start to a key CLL drug be possible? new study reexamines the risk
NCT ID NCT07691047
First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time
Summary
This study looks at people with chronic lymphocytic leukemia (CLL) who are about to start treatment with venetoclax, a targeted therapy. Doctors want to see if starting with other drugs first lowers the risk of tumor lysis syndrome, a dangerous side effect where cancer cells break down too quickly. By reassessing this risk, the goal is to simplify prevention steps and make treatment safer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- venetoclax
- What this could lead to
- If successful, this could simplify how doctors manage the risk of tumor lysis syndrome, potentially reducing hospital stays and making treatment safer for CLL patients.
- What could go wrong
- This is an observational reassessment, not a test of a new drug. The findings may not change current practice if the risk remains high or if the simplified approach proves unsafe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinique de l'Europe
Amiens, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital Privé du Confluent
Nantes, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.